Clinical phase I and pharmacokinetic study of S 16020, a new olivacine derivative: Report on three infusion schedules

Annals of Oncology

Volumn 13, Issue 12, 2002, Pages 1925-1934

  Awada, Ahmad ^a   Giacchetti, S ^b   Gerard, B ^c   Eftekhary, P ^b   Lucas, C ^c   de Valeriola, D ^a   Poullain, M G ^c   Soudon, J ^d   Dosquet, C ^b   Brillanceau, M H ^e   Giroux, B ^c   Marty, M ^b   Bleiberg, H ^a   Calvo, F ^b   Piccart, M ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b SAINT LOUIS HOSPITAL   (France)

^c INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^d Pharmacell   (France)

^e Servier UK   (United Kingdom)

Author keywords

Clinical phase I; Olivacine derivative; S 16020; Solid tumors

Indexed keywords

AMINEPTINE; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; BLEOMYCIN; CISPLATIN; CYTARABINE; CYTOKINE; CYTOTOXIC AGENT; DIOXIN; ELLIPTICINE; FLUOROURACIL; GEMCITABINE; GYRASE INHIBITOR; ISOTRETINOIN; METHYLPREDNISOLONE; METOCLOPRAMIDE; N (2 DIMETHYLAMINOETHYL) 9 HYDROXY 5,6 DIMETHYL 6H PYRIDO[4,3 B]CARBAZOLE 1 CARBOXAMIDE; OLIVACINE; OPIATE; PARACETAMOL; SEROTONIN 3 ANTAGONIST; STEROID;

ACNE; ADULT; AGED; AGITATION; ALOPECIA; ANOREXIA; ANTIBODY DETECTION; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; CANCER PAIN; CELL LINE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DOSE RESPONSE; DRUG ACTIVITY; DYSPNEA; EPIDERMOID TUMOR; FACE EDEMA; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEMATOLOGIC DISEASE; HEMOLYSIS; HUMAN; IMMUNOGENICITY; INFLAMMATION; LIVER TOXICITY; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MULTIDRUG RESISTANCE; MYALGIA; NASOPHARYNX CARCINOMA; NAUSEA; PAIN; PHASE 1 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; PRURITUS; RASH; SEPSIS; SEPTIC SHOCK; SHOCK; SKIN TOXICITY; SOFT TISSUE METASTASIS; TUMOR NECROSIS; VOMITING;

EID: 0036920041     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf321     Document Type: Article

References (20)

1. Jasztold-Howorko R, Landras C, Pierre A et al. Synthesis and evaluation of 9-hydroxy-5-methyl-(5,6-dimethyl)-6H-pyrido [4,3-b] carbazole-1-N-[(dialkylamino) alkyl] carboxamides: a new promising series of antitumour olivacine derivatives. J Med Chem 1994; 37: 2445-2452.
2. Soudon J, Poullain MG, Giroux B. Apoptosis triggering is a determinant of the cytotoxicity to S 16020 independent of p53 status. Prod Am Assoc Cancer Res 1999; 40: 581 (Abstr 3833).
3. Leonce S, Perez V, Casabianca-Pignede MR et al. In vitro cytotoxicity of S 16020-2, a new olivacine derivative. Invest New Drugs 1996; 14: 169-180.
4. Guilbaud N, Kraus-Berthier L, Saint-Dizier D et al. In vivo antitumour activity of S 16020-2, a new olivacine derivative. Cancer Chemother Pharmacol 1996; 38: 513-521.
5. Kraus-Berthier L, Guilbaud N, Jan M et al. Experimental antitumour activity of S 16020-2 in a panel of human tumours. Eur J Cancer 1997; 33: 1881-1887.
6. Guilbaud N, Kraus-Berthier L, Saint-Dizier D et al. Antitumour activity of S 16020-2 in two orthotopic models of lung cancer. Anticancer Drugs 1997; 8: 276-282.
7. I.R.I.S. Cancer Treatment Division. S 16020: Investigator's Brochure No. 4. February 2000.
8. Anticancer medicinal products. Revised guidance issued for comment by the Committee for Proprietary Medicinal Products. Regul Aff J 1996; 843-848.
9. Alberici GF, Fellous R, Bidart JM et al. Human antibodies to the anti-neoplastic drug elliptinium: characterization and structure activity relationships. J Allerg Clin Immunol 1986; 77: 624-630.
10. Pallardy M, Alberici GF, Dessaux JJ et al. Polyclonal antibodies to elliptinium acetate: structure activity relationships and comparison with human anti-elliptinium IgM. Int J Immunopharmacol 1987; 9: 151-156.
11. Gibaldi M, Perrier D. Pharmacokinetics. 2nd edition. New York, NY: Marcel Dekker, Inc. 1982.
12. Huet P, Dandurand M, Joujoux JM et al. L'acné induite par l'amineptine: une toxidermie annexielle. Ann Dermatol Venereol 1996; 123: 817-820.
13. Fazio M, Afa G, Sacerdoti G et al. Acne iatrogena da amineptina: osservazioni cliniche e biochemiche. G Ital Dermat Venereol 1992; 127: 429-433.
14. Vexiau P, Gourmel B, Julien R. Severe acne-like lesions caused by amineptine overdose. Lancet 1988; 1: 585.
15. Jeffcoate WJ. Chronic fatigue syndrome and functional hypoadrenia-fighting vainly the old ennui. Lancet 1999; 353: 424-425.
16. Morant R. Asthenia: an important symptom in cancer patients. Cancer Treat Rev 1996; 22 (Suppl A): 117-122.
17. Von Hoff D. Asthenia. Cancer Ther 1998; 1: 1-14.
18. Glaus A. Fatigue: an orphan topic in patients with cancer. Eur J Cancer 1998; 34: 1649-1651.
19. Burstein H. Side effects of chemotherapy. Case 1. Radiation recall dermatitis from gemcitabine. J Clin Oncol 2000; 18: 693-698.
20. Anderson B, Luna M, Yee C et al. Fatal pulmonary failure complicating high-dose cytosine arabinoside therapy in acute leukemia. Cancer 1990; 65: 1079-1084.